Pyrimidinylphenyl ester compound

Abstract: Pyrimidinylphenyl ester compounds of the general formula: wherein R* represents an optically active alkyl group having an asymmetric carbon atom, R represents a straight-chain alkyl group or a straight-chain alkoxy group and A represents - -O- or -O-.

Description: This invention relates to pyrimidinylphenyl ester compounds. In particular, the present invention provides liquid crystal pyrimidinylphenyl ester compounds which may be blended in ferroelectric liquid crystal compositions to improve the properties thereof. The compounds of the present invention are usable in display elements or display devices, utilising the electro-optical effects of the liquid crystal compositions. (S)-2-Methylbutyl p-(p-n-decyloxybenzylideneamino)cinnamate (DOBAMBC) is known. This Schiff base compound has been studied as a ferroelectric liquid crystal material and various related compounds have been prepared as a result. Known examples of these compounds are those of the general formula: wherein X represents H, Cl or CN, Y represents Cl or C₂H₅ and represents an asymmetric carbon atom. However, the use of these compounds is limited, since the temperature at which they are in the chiral smectic phase is higher than room temperature and their chemical stability is low because they contain a Schiff base. Compounds of the structural formula: proposed as compounds free of the above-described defects have attracted public attention. Further, Horst Zaschke and Reinhard Stolle described various compounds of the formula: wherein m is 1 to 11 and n is 5 to 8, in Z. Chem 1975 15 (11), 441 to 3. US Patent Specification No. 4311610 (equivalent to EP-A-25,119) disclosed compounds having a structure. However, neither group of compounds is disclosed as having a cholesteric liquid crystal phase. EP-A-25,119 discloses compounds having a core each of which show a nematic phase. EP-A-25,119 does not suggest substituents containing a chiral center. EP-A-131,373 discloses chiral smectic compounds with a high response rate. EP-A-131,373 does not suggest a structural element of the formula as a core. EP-A-25,119 says nothing about asymmetric carbon atoms or optical activity. Furthermore, neither EP-A-25,119 nor EP-A-131,373 discloses compounds showing cholesteric phase and effective to lower the phase transition temperature of chiral smectic C phase by blending the compounds with ferro-electric chiral smectic liquid crystal compounds. EP-A-225 195 discloses phenylpyrimidine - based compounds falling within a broad generic formula, eg. those containing the partial formula EP-A-164 814 discloses compounds of the formula where Y is -R, -OR, -COR, -OCOR,-OCOOR or -COOR and R is C₁₋₁₈alkyl. These compounds do not contain a phenylpyrimidyl residue. The present invention seeks to provide pyrimidinyl-phenyl ester compounds which can be blended in ferroelectric liquid crystal compositions to improve the properties thereof. More specifically, the present invention is based upon the creation of new compounds having novel substituents, and the discovery of compounds showing the cholesteric phase or the cholesteric and smectic C* phases by blending the compounds with ferroelectric chiral smectic liquid crystal compounds. The problem solved is that the temperature range of the SmC* phase (especially downward) is extended. The compounds of the present invention have a cholesteric phase, or cholesteric and smectic C* phases and, in a mixture containing at least one of the compounds, have a ferroelectric SmC* phase in a wide temperature range. The cholesteric phase serves good orientation characteristics. Therefore, the temperature transition phase can be reduced by as much as 10°C for such mixture. Such mixtures also provide a high speed response to an electric field. According to one aspect of the present invention there is provided a pyrimidinylphenyl ester compound of the formula: wherein R₁ represents a straight chain alkyl group having 1 to 5 carbon atoms, R₂ represents a straight chain alkyl group of 1 to 4 carbon atoms, R represents a straight chain alkyl or alkoxy group having 5 to 12 carbon atoms, represents an asymmetric carbon atom, and n is an integer. According to another aspect of the present invention there is provided a pyrimidinylphenyl ester compound of the formula: wherein R₃ represents a straight chain alkyl group having 1 to 6 carbon atoms, R represents a straight chain alkyl or alkoxy group having 5 to 12 carbon atoms, and represents an asymmetric carbon atom. According to a further aspect of the present invention there is provided a ferro-electric liquid crystal composition including at least one pyrimidinylphenyl ester compound according to the present invention. The compounds of the above formula (I) are prepared by reacting a compound of the formula (II): wherein R is as defined above, with a compound of the formula (III): wherein R*-A- represents and R₁, R₂ and R₃ are as defined above, or a reactive derivative thereof. The substituents R of the compounds of the formula (II) used herein are each in a straight chain alkyl or alkoxy group such as a pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, pentyloxy, hexyloxy, heptyloxy, nonyloxy, decyloxy, undecyloxy or dodecyloxy group. An example of the substituent R* is an optically active alkyl group having an asymmetric carbon atom of the formula: wherein R₁ represents a methyl or ethyl group, R₂ represents an alkyl group having 1 to 4 carbon atoms, n is an integer, and one of elements directly bonded with the active carbon atom is an oxygen atom. The configuration around the C* atom is either (S) or (R). Examples of the substituents R* include (S)- or (R)-2- methyloxybutyl, (S)- or (R)-2-ethoxybutyl, (S)- or (R)-2- propoxybutyl, (S)- or (R)-2-butoxybutyl, (S)- or (R)-2-methyloxypropyl, (S)- or (R)-2-ethoxypropyl, (S)- or (R)-3-methoxybutyl, (S)- or (R)-3-ethoxybutyl, (S)- or (R)-3-methoxypentyl and (S)- or (R)-3-ethoxypentyl groups. A further example of the substituent R* has the formula: where R₃ represents a straight chain alkyl group having 1 to 6 carbon atoms. The configuration around the C* atom is either (S) or (R). Examples of the substituents R* include (S)- or (R)-1-methoxyethyl, (S)- or (R)-1-ethoxyethyl, (S)- or (R)-1-propoxyethyl, (S)- or (R)-1-butoxyethyl, (S)- or (R)-1-pentyloxyethyl, or (S)- or (R)-1-hexyloxyethyl. Both starting compounds are dissolved in a suitable solvent (such as ethyl acetate, methyl acetate, ethyl ether, tetrahydrofuran, dioxane, dimethylformamide, dimethyl sulphoxide or ethylene glycol dimethyl ether) and the reaction is conducted in the presence of a condensing agent such as N,N'-dicyclohexylcarbodiimide, thionyl chloride or phosphorus oxychloride. The reaction proceeds smoothly when a tertiary amine such as 4-dimethylaminopyridine, dimethylaniline or triethylamine is also used. Examples of the reactive derivatives of the compounds of the formula (III) include acyl halides (such as acyl chlorides formed by the reaction with thionyl chloride), active esters (such as those formed with p-nitrophenol) and mixed acid anhydrides (such as those formed with ethoxycarbonyl chloride). The reactive derivatives are subjected to the reaction in the presence of a tertiary amine. The compound (II) used as the starting material is prepared from β-dimethylamino-α-(n-alkyl or alkoxy)acrolein and hydroxybenzamidine. The compound is prepared from optically active lactic acid. In particular, lactic acid is chemically modified repeatedly to modify the number n , for example, as follows: The above-mentioned cycle is repeated to increase the number of carbon atoms one by one. Thus, an optically active alcohol having a number n increased one by one is obtained. A reactive derivative such as that of the formula: is derived from the product. The derivative is reacted with hydroxyphenyl benzoate to remove the pyranyl group. Then, the hydroxyl group is alkylated with an alkyl halide (R₂X). After hydrolysis, a compound of the formula: is obtained. A compound of the formula is obtained by following procedure using as a starting material. The starting compounds used in the present invention are prepared in a manner described in the following examples. The liquid crystal compounds of the present invention are in the cholesteric phase over a wide temperature range. The temperature range of the mixture of ferro-electric liquid crystal compounds, in which at least one liquid crystal compound according to the present invention is blended, can be widened. Especially, the phase transition temperature, on the lower temperature side, of chiral smectic C phase of the mixture becomes lower. Also the response characteristifc and domain condition can be improved by blending the compound with a ferro-electric liquid crystal compound or composition. The following examples will further illustrate the present invention. Comparative Example 1 Preparation of (S)-2-{4'-[4''-(2-methyl)butyryloxy]benzoyloxy}phenyl-5-n-octyloxypyrimidine: 2.2 g (0.0099 mol) of (S)-4-(2-methyl)butyryloxybenzoic acid and 3.0 g (0.010 mol) of 2-(4-hydroxy)phenyl-5-n-octyloxypyrimidine were dissolved in 25 ml of ethyl acetate. 2.3 g (0.011 mol) of N,N'-dicyclohexylcarbodiimide and 0.12 g (0.098 mmol) of 4-dimethylaminopyridine were added to the solution and the mixture was stirred at room temperature for 7 h. After completion of the reaction, the reaction mixture was poured into ice water and the organic layer was separated. After extraction with ethyl acetate followed by washing with a 10% aqueous sodium hydroxide solution, then with water and finally with a saturated NaCl aqueous solution, the product was dried over magnesium sulfate and concentrated. The obtained product was purified according to silica gel column chromatography and re-crystallised from ethanol to obtain 1.7 g of the intended compound. [α] 25 / D = +9.90° (C=2.19, CHCl₃) IRγ max cm⁻¹: 1760, 1740, 1445, 1270, 1205, 1160, 1080, 885, 785 'H-NMR (CDCl₃, 60 MHz) δ(ppm): 0.67 ∼ 2.13 (m, 25H) 2.33 ∼ 2.90 (m, 1H) 4.07 (t, 2H) 7.21 (d, 2H) 7.29 (d, 2H) 8.23 (d, 2H) 8.37 (s, 2H) 8.42 (d, 2H) The phase transition temperatures of the compound were as follows: Comparative Example 2 Preparation of (S)-2-{4'-[4''-(2-methyl)butyryloxy]-benzoyloxy}phenyl-5-n-octylpyrimidine: 1.5 g (0.0068 mol) of (S)-4-(2-methyl)butyryloxy-benzoic acid, 2.0 g (0.0067 mol) of 2-(4-hydroxy)phenyl-5-n-octylpyrimidine, 1.5 g (0.0073 mol) of N,N'-dicyclohexylcarbodiimide, 80 mg (0.066 mmol) of 4-dimethylaminopyridine and 20 mℓ of ethyl acetate were reacted at room temperature for 10 h and then the same procedure as in Example 1 was repeated to obtain 1.1 g of the intended compound. [α] 25 / D = +10.2° (C=2.08, CHCl₃) IRγ max cm⁻¹: 1760, 1735, 1430, 1270, 1200, 1165, 1075 'H-NMR (CDCl₃, 60 MHz) δ(ppm): 0.60 ∼ 1.93 (m, 2H) 2.27 ∼ 2.90 (m, 3H) 7.13 (d, 2H) 7.23 (d, 2H) 8.13 (d, 2H) 8.40 (d, 2H) 8.50 (s, 2H) The phase transition temperatures of the compound were as follows: Comparative Example 3 Preparation of (S)-2-{4'-[4''-(2-methylbutoxy)phenylcarbonyloxy]phenyl}-5-n-octylpyrimidine: 1.6 g (0.0077 mol) of (S)-4-(2-methylbutoxy)benzoic acid and 2.3 g (0.0077 mol) of 2-(4-hydroxy)phenyl-5-n-octylpyrimidine were dissolved in 25 mℓ of ethyl acetate. 1.9 g (0.0092 mol) of N,N'-dicyclohexylcarbodiimide and 90 mg (0.074 mmol) of 4-dimethylaminopyridine were added to the solution and the mixture was stirred at room temperature for 17 h. After completion of the reaction, the reaction mixture was poured into ice water and extracted with ethyl acetate. The extract was washed with a 10% aqueous sodium hydroxide solution, then water and finally with a saturated NaCl aqueous solution, dried over magnesium sulfate and concentrated. The product was purified according to silica gel column chromatography and then re-crystallised from ethanol to obtain 1.3 g of the intended compound. [α] 25 / D = + 5.4° (C=2.05, CHCl₃) IRγ max cm⁻¹: 1735, 1610, 1435, 1260, 1200, 1165, 1080, 850, 655 'H-NMR (CDCl₃, 60 MHz) δ(ppm): 0.63 ∼ 2.17 (m, 24H) 2.58 (t, 2H) 3.82 (d, 2H) 6.89 (d, 2H) 7.26 (d, 2H) 8.03 (d, 2H) 8.41 (d, 2H) 8.52 (s, 2H) The phase transition temperatures of the compound were as follows: Example 1 Preparation of (S)-2-{4'-[4''-(2-methoxy)butoxy]benzoyloxyphenyl}-5-n-octyloxypyrimidine: 1.0 g (0.0045 mol) of (S)-4-(2-methoxybutoxy)benzoic acid and 1.34 g (0.0045 mol) of 2-(4-hydroxy)phenyl-5-n-octyloxypyrimidine were dissolved in 30 mℓ of ethyl acetate. 1.1 g (0.0053 mol) of N,N'-dicyclohexylcarbodiimide and 50 g (0.041 mmol) of 4-dimethylaminopyridine were added to the solution and the reaction was conducted at room temperature for 7 h. After completion of the reaction, the reaction mixture was poured into water and extracted with ethyl acetate. The extract was washed with a 10% aqueous sodium hydroxide solution, then with water and finally with a saturated NaCl aqueous solution, dried over magnesium sulfate and concentrated. The product was purified according to silica gel column chromatography and then re-crystallised from ethanol to obtain 0.48 g of white crystals. [α] 25 / D = -12.0° (C 2.00, CHCl₃) IRγ max cm⁻¹: 1740, 1555, 1470, 1250, 1100, 1080, 885, 840, 780, 760 'H-NMR (CDCl₃, 60 MHz) δ(ppm): 0.66 ∼ 2.07 (m, 20H) 3.27 ∼ 3.70 (s, 1H) 3.43 (s, 3H) 3.90 ∼ 4.23 (m, 4H) 6.93 (d, 2H) 7.27 (d, 2H) 8.10 (d, 2H) 8.37 (d, 2H) 8.40 (s, 2H) The phase transition temperatures of the compound were as follows: Example 2 Preparation of (S)-2-{4'-[4''-(2-methoxy)butoxy]benzoyloxyphenyl}-5-n-octylpyrimidine: 0.4 g (0.0018 mol) of (S)-4-(2-methoxy)butoxybenzoic acid, 0.54 g (0.0018 mol) of 2-(4-hydroxy)phenyl-5-n-octylpyrimidine, 10 mℓ of ethyl acetate, 0.41 g (0.002 mol) of N,N'-dicyclohexylcarbodiimide and 20 mg (0.016 mmol) of 4-dimethylaminopyridine were reacted at room temperature for 9 h and then the same procedure as in Comparative Example 1 was repeated to obtain 0.2 g of white crystals. [α] 25 / D = -12.9° (C 1.52, CHCl₃) IRγ max cm⁻¹: 1745, 1610, 1430, 1260, 1200, 1165, 1080 'H-NMR (CDCl₃, 60 MHz) δ(ppm): 0.70 ∼ 2.00 (m, 20H) 2.80 ∼ 2.43 (m, 2H) 3.33 ∼ 3.67 (m, 1H) 3.43 (s, 3H, -OCH₃) 4.03 (d, 2H) 6.94 (d, 2H) 7.20 (s, 2H) 7.27 (d, 2H) 8.10 (d, 2H) 8.43 (d, 2H) 8.55 (d, 2H) The phase transition temperatures of the compound were as follows: Example 3 Preparation of (S)-2-{4'-[4''-(2-ethoxy)propoxy]benzoyloxyphenyl}-5-n-octyloxypyrimidine: 0.5 g (0.0022 mol) of (S)-4-(2-ethoxy)propoxybenzoic acid, 0.67 g (0.0022 mol) of 2-(4-hydroxy)phenyl-5-n-octyloxypyrimidine, 18 mℓ of ethyl acetate, 0.51 g (0.0025 mol) of N,N'-dicyclohexylcarbodiimide and 30 mg (0.025 mmol) of 4-dimethylaminopyridine were reacted at room temperature for 23 h and then the same procedure as in Comparative Example 1 was repeated to obtain 0.3 g of white crystals. [α] 25 / D = -11.0° (C 2.00, CHCl₃) IRγ max cm⁻¹: 1740, 1470, 1450, 1250, 1080, 885, 780, 760 'H-NMR (CDCl₃, 60 MHz) δ(ppm): 0.50 ∼ 2.13 (m, 21H) 3.42 ∼ 3.90 (m, 3H) 3.90 ∼ 4.30 (m, 4H) 6.90 (d, 2H) 7.28 (d, 2H) 8.13 (d, 2H) 8.41 (d, 2H) 8.42 (s, 2H) The phase transition temperatures of the compound were as follows: Example 4 A liquid crystal compound, i.e. (S)-2-{4'-[4''-(2-methoxy)propoxy]benzoyloxyphenyl}-5-n-octylpyrimidine, prepared in the same manner as in Comparative Examples 1 to 3 had the following phase transition temperatures: Example 5 Preparation of (s)-2-[4-{4'-(2-methoxy)propionyloxy} benzoyloxy]phenyl-5-n-octylpyrimidine. 2.3g (0.01 mol) of (s)-4-(2-metoxypropionyloxy) benzoic acid and 2.9g (0.01 mol) 2-(4-hydroxy)phenyl -5-n-octylpyrimidine were dissolved in 25ml of ethyl acetate, and 2.3g (0.01 mol) of DCC and 0.13g (0.0011 mol) of DMAP were added to the solution. The mixture was stirred for 26 hours at room temperature. After completion of the reaction, the precipitated product was filtered, and the filtrate was concentrated. the concentrated product was isolated according to silica gel column chromatography and then recrystallized from ethanol, yielding the intended compound. The yield was 0.28g. [α] 25 / D =31.1°(C=2.0, CHCl₃) IR(nujol)γ max, cm⁻¹ = 1780, 1740, 1435, 1270, 1200, 1165 H'-NMR (CDCl₃) (ppm) = 0.50 ∼ 2.00 (m, 18H) 2.60 (t, 2H) 3.47 (s, 3H) 4.10 (q, 1H) 7.23 (d, 2H) 8.28 (d, 2H) 8.20 (d, 2H) 8.45 (d, 2H) 8.57 (s, 2H) The phase transition temperatures were as follows: Example 6 Preparation of (s)-2-[4-{4'-(2-butoxy)propionyloxy} benzoyloxy]phenyl-5-n-octylpyrimidine. 1.5g (0.0056 mol) of (s)-4-(2-butoxypropionyloxy) benzoic acid and 1.6g (0.0056 mol) of 2-(4-hydroxy)phenyl-5-n-octylpyrimidine were dissolved in 15ml of ethyl acetate, and 1.3g (0.0063 mol) of DCC and 0.07g (0.00057 mol) of DMAP were added to the solution. Then, the mixture was stirred for 19 hours at room temperature and then the same procedure as in Example 5 was conducted to obtain 0.39g of the intended compound. The yield was 0.39g. [α] 25 / D =30.2°(C=2, CHCl₃) IR(nujol)γmax, cm⁻¹ = 1780, 1735, 1470, 1440, 1265, 1200 H'-NMR (CDCl₃) (ppm) = 0.63 ∼ 2.07 (m, 25H) 2.62 (t, 2H) 3.53 (t, 2H) 4.18 (q, 1H) 7.23 (d, 2H) 7.40 (d, 2H) 8.22 (d, 2H) 8.47 (d, 2H) 8.57 (d, 2H) The phase transition temperatures were as follows: Example 7 Preparation of (s)-2-[4-{4'-(2-butoxy)propionyloxy} benzoyloxy]phenyl-5-n-octyloxypyrimidine. 1.5g (0.0056 mol) of (s)-4-(2-butoxypropionyloxy) benzoic acid and 1.7g (0.0056 mol) of 2-(4-hydroxy)phenyl -5-n-octyloxypyrimidine were dissolved in 15ml of ethyl acetate, and 1.3g (0.0063 mol) of DCC and 0.07g (0.00057 mol) of DMAP were added to the solution. The, the mixture was stirred for 15 hours at room temperature and then the same procedure as in Example 5 was conducted to obtain 0.33g of the intended compound. [α] 25 / D =27.8°(C=2.0, CHCl₃) IR(nujol)γmax, cm⁻¹ = 1780, 1750, 1470, 1450, 1275, 1205 H'-NMR (CDCl₃) f(ppm) ; 0.63 ∼ 2.00 (m, 25H) 3.37 ∼ 3.80 (m, 2H) 4.08 (t, 2H) 4.18 (q, 1H) 7.23 (d, 2H) 7.30 (d, 2H) 8.25 (d, 2H) 8.42 (d, 2H) 8.43 (s, 2H) The phase transition temperatures were as follows: The spontaneous polarization of this compound shows "positive" and the helix of Sc* phase is counterclockwise. Example 8 The compounds prepared in Examples 1, 2 and 4 were blended in the following ferroelectric liquid crystal composition A and the properties of them were compared. Composition A: The response speed was determined in terms of the minimum pulse width necessary to cause switching of display patterns when the liquid crystal was poured into a cell of a clearance of 1.7 µm and pulses having various shapes were applied to the cell by varying the voltage from -20 to +20 V. It can be understood from the above table that when a suitable amount of the compound of the present invention is blended in the composition A, the temperature range in which the Sc* phase is present can be widened in both upper and lower temperature sides. In addition, a composition having a Ch phase can be obtained as shown in the case of the blend of the composition A and the compound prepared in Examples1,2 and 4. It is also possible to increase the speed of response as observed in the blend of the composition A and the compound prepared in Example 4. Referential Example 1 Preparation of benzyl (S)-4-(2-methyl)butyryloxybenzoate: 4.5 g (0.044 mol) of (S)-2-methylbutyric acid and 10 g (0.044 mol) of benzyl 4-hydroxybenzoate were dissolved in 50 mℓ of ethyl acetate. 10 g (0.049 mol) of N,N'-dicyclohexylcarbodiimide and 0.54 g (0.44 mmol) of 4-dimethylaminopyridine were added to the solution and the mixture was stirred at room temperature for 18 h. After completion of the reaction, the reaction mixture was poured into water. The organic layer was separated, extracted with ethyl acetate and washed with a 10% aqueous sodium hydroxide solution, then with water and finally with a saturated aqueous common salt solution. The product was dried over magnesium sulfate and concentrated. The residue was purified according to silica gel column chromatography to obtain 9.3 g of the intended compound. IRγ max cm⁻¹: 1760, 1720, 1610, 1510, 1270, 1210, 1180, 1100, 1020, 760, 700 'H-NMR (CDCl₃, 60 MHz) δ(ppm): 0.82 ∼ 1.42 (m, 6H) 1.42 ∼ 2.02 (m, 2H) 2.33 ∼ 2.80 (m, 1H) 5.28 (s, 2H) 7.06 (d, 2H) 7.32 (s, 5H) 8.02 (d, 2H) Referential Example 2 Preparation of (S)-4-(2-methyl)butyryloxybenzoic acid: 9.0 g (0.029 mol) of benzyl (S)-4-(2-methyl)butyryloxybenzoate and 0.9 g of palladium/carbon were placed in 90 mℓ of ethanol to conduct catalytic reduction. After 1.5 h, an insoluble matter was filtered out and the filtrate was concentrated to obtain 6.3 g of crude intended compound. IRγ max cm⁻¹: 3200 ∼ 2450 (br), 1770, 1680, 1605, 1430, 1320, 1295, 1210, 1165, 1105, 760, 550 'H-NMR (CDCl₃, 60 MHz) δ(ppm): 0.83 ∼ 1.43 (m, 6H) 1.43 ∼ 2.13 (m, 2H) 2.33 ∼ 2.87 (m, 1H) 7.13 (d, 2H) 8.08 (d, 2H) 10.40 (br, 1H) Referential Example 3 Preparation of (S)-4-(2-methyl)butyryloxybenzoic acid: 5 g (0.036 mol) of 4-hydroxybenzoic acid was dissolved in 30 mℓ of ethanol. 6 g (0.040 mol) of (S)-2-methylbutyl bromide and 15 mℓ of a 10% aqueous potassium hydroxide solution were added to the solution and the mixture was refluxed for 5 h. After completion of the reaction, the reaction mixture was acidified with hydrochloric acid to form precipitates. The precipitates were recovered by filtration, washed and dried to obtain 3.1 g of the intended compound. Referential Example 4 Synthesis of 2-(4-hydroxy)phenyl-5-n-octylpyrimidine: 4.32 g of 4-hydroxybenzamidine hydrochloride and 5.7 g of β-dimethylamino-α-n-octyloxyacrolein were dissolved in 40 mℓ of ethanol. 19.3 g of a 28% solution of sodium methylate in methanol was added to the solution and the mixture was refluxed for 8 h. After completion of the reaction, the reaction mixture was poured into ice-water, acidified with a dilute aqueous sulfuric acid solution and extracted with ethyl acetate. The extract was washed with a saturated aqueous sodium hydrogencarbonate solution and then with a saturated aqueous common salt solution and concentrated to obtain 7.1 g of an oily product. It was recrystallized from n-hexane/ethanol to obtain 2.79 g of the intended compound. IRγ max cm⁻¹: 3350 ∼ 3050, 1610, 1595, 1435, 1280, 1245, 1175, 790 'H-NMR (CDCl₃, 60 MHz) δ(ppm): 0.6 ∼ 2.2 (m, 17H) 4.02 (t, 2H) 6.85 (d, 2H) 8.16 (d, 2H) 8.43 (s, 2H) Referential Example 5 Preparation of (S)-ethyl 4-(2-tetrahydropyranyloxy)butoxybenzoate: 5 g (0.030 mol) of ethyl 4-hydroxybenzoate was added to 1.6 g (0.033 mol) of 50% sodium hydride and 50 mℓ of dimethylformamide under stirring at room temperature. The mixture was stirred for 30 min. 9.9 g (0.030 mol) of (S)-2-tetrahydropyranyloxybutoxy p-toluenesulfonate was added thereto and the mixture was stirred at 80°C for 10 h. Then, the mixture was poured into ice-water and extracted with ethyl acetate. The extract was washed with a 10% aqueous sodium hydroxide solution and then with a saturated aqueous common salt solution, dried and concentrated to obtain 8.8 g of the crude product. IRγ max cm⁻¹: 1720, 1605, 1515, 1280 ∼ 1250 (br), 1170, 1030, 770 Referential Example 6 Preparation of (S)-ethyl 4-(2-hydroxy)butoxybenzoate: 8.5 g (0.026 mol) of (S)-ethyl 4-(2-tetrahydropyranyloxy)butoxybenzoate was dissolved in 43 mℓ of ethanol. 0.2 g (0.0011 mol) of p-toluenesulfonic acid monohydrate was added to the solution and the mixture was refluxed for 3 h. Then, the reaction mixture was concentrated. Water was added thereto. After extraction with ethyl acetate, the extract was washed with water, dried over magnesium sulfate and concentrated. The product was purified according to silica gel column chromatography to obtain 3.4 g of white crystals. IRγ max cm⁻¹: 3600 ∼ 3200 (br), 1710, 1610, 1515, 1290 ∼ 1230 (br), 1170, 1100, 850, 770 Referential Example 7 Preparation of (S)-ethyl 4-(2-methoxy)butoxybenzoate: 2.0 g (0.0084 mol) of (S)-ethyl 4-(2-hydroxy)butoxybenzoate was added to 0.44 g (0.0092 mol) of 50% sodium hydride and 15 mℓ of tetrahydrofuran under stirring at room temperature. 0.2 g (0.0011 mol) of hexamethylphosphoric triamide was added thereto. The mixture was stirred for 1 h. 1.43 g (0.01 mol) of methyl iodide was added thereto and the mixture was stirred at 40°C for 1.5 h. After completion of the reaction, the reaction mixture was poured into ice-water and extracted with ethyl acetate. The extract was washed with a 10% aqueous sodium hydroxide solution, then with water and finally with a saturated aqueous common salt solution, dried over magnesium sulfate and concentrated to obtain 1.9 g of the crude product. IRγ max cm⁻¹: 1710, 1605, 1515, 1280, 1250, 1170, 1100, 850, 770 Referential Example 8 Preparation of (S)-4-(2-methoxy)butoxybenzoic acid: 1.9 g (0.0075 mol) of S-ethyl 4-(2-methoxy)butoxybenzoate was dissolved in 10 mℓ of ethanol. 5 mℓ of a 10% aqueous sodium hydroxide solution was added to the solution. The mixture was stirred for 30 min, acidified with hydrochloric acid and extracted with ethyl acetate. The extract was washed with an aqueous sodium hydrogencarbonate solution, dried over magnesium sulfate and concentrated to obtain 1.9 g of an oily product. n-Hexane was added to the product to form crystals, which were filtered, washed with n-hexane and dried to obtain 1.2 g of the intended compound. IRγ max cm⁻¹: 3100 ∼ 2500, 1680, 1605, 1430, 1300, 1255, 850, 770, 640 'H-NMR (CDCl₃, 60 MHz) δ(ppm): 0.87 ∼ 1.37 (m, 3H) 1.37 ∼ 1.93 (m, 2H) 3.27 ∼ 3.63 (m, 1H) 3.43 (s, 3H) 4.00 (d, 2H) 6.87 (d, 2H) 7.97 (d, 2H) 9.87 (br, 1H) Referential Example 9 Preparation of (S)-ethyl 4-(2-tetrahydropyranyloxy)propoxybenzoate: 1.0 g (0.021 mol) of 50% sodium hydride, 25 mℓ of dimethylformamide, 3.2 g (0.019 mol) of ethyl 4-hydroxybenzoate and 6.1 g (0.019 mol) of (S)-2-tetrahydropyranyloxypropoxy p-toluenesulfonate were reacted at 60°C for 8 h. Then the same procedure as in Referential Example 1 was repeated to obtain 5.0 g of the crude product. IRγ max cm⁻¹: 1715, 1610, 1280, 1255, 1170, 1120, 1035, 770 Referential Example 10 Preparation of (S)-ethyl 4-(2-hydroxy)propoxybenzoate: A mixture of 4.5 g (0.014 mol) of (S)-ethyl 4-(2-tetrahydropyranyloxy)propoxybenzoate, 0.2 g (0.0011 mol) of p-toluenesulfonic acid monohydrate and 45 mℓ of methanol were refluxed for 1 h. Then the same procedure as in Referential Example 2 was repeated to obtain 2.2 g of the crude product. IRγ max cm⁻¹: 3600 ∼ 3200 (br), 1710 (br), 1610, 1515, 1300 ∼ 1220 (br), 1170, 1100, 1030, 770 Referential Example 11 Preparation of (S)-4-(2-ethoxy)propoxybenzoic acid: 2.2 g (0.0098 mol) of (S)-ethyl 4-(2-hydroxy)propoxybenzoate and 0.2 g (0.0011 mol) of hexamethylphosphoric triamide were added to a mixture of 0.52 g (0.011 mol) of 50% sodium hydride and 15 mℓ of tetrahydrofuran under stirring. After 1 h, 1.8 g (0.012 mol) of methyl iodide was added thereto and the mixture was refluxed for 2 h. Then the mixture was poured into ice-water and extracted with ethyl acetate. The extract was washed with a 10% aqueous sodium hydroxide solution and then with a saturated aqueous common salt solution, dried over magnesium sulfate and concentrated. 20 mℓ of ethanol was added thereto to obtain a solution. The solution was refluxed together with a 10% aqueous sodium hydroxide solution for 1 h to conduct hydrolysis. After completion of the hydrolysis, the reaction mixture was poured into ice-water and extracted with ethyl acetate. After the same procedure as that described above, 1.4 g of an oily product was obtained. The product was purified according to silica gel column chromatography to obtain 0.76 g of the product. [α] 25 / D = -14.3° (C 1.05, CHCl₃) IRγ max cm⁻¹: 3300 ∼ 2400 (br), 1690, 1610, 1460, 1250, 1170, 850, 770 'H-NMR (CDCl₃, 60 MHz) δ(ppm): 0.70 ∼ 1.90 (m, 6H) 3.40 ∼ 4.23 (m, 5H) 6.90 (d, 2H) 8.03 (d, 2H) 11.70 (br, 1H)

Claims: A pyrimidinylphenyl ester compound of the formula: wherein R₁ represents a straight-chain alkyl group having 1 to 5 carbon atoms, R₂ represents a straight chain alkyl group of 1 to 4 carbon atoms, R represents a straight chain alkyl or alkoxy group having 5 to 12 carbon atoms, represents an asymmetric carbon atom, and n is an integer. A pyrimidinylphenyl ester compound of the formula: wherein R₃ represents a straight chain alkyl group having 1 to 6 carbon atoms, R represents a straight chain alkyl or alkoxy group having 5 to 12 carbon atoms, and represents an asymmetric carbon atom. A compound according to claim 1, which compound is (S)-2-{4'-[4''(2-methoxy)butoxy]-benzoyloxyphenyl}-5-n-octyloxypyrimidine. A compound according to claim 1, which compound is (S)-2-{4'-[4''(2-methoxy)butoxy]-benzoyloxyphenyl}-5-n-octylpyrimidine. A compound according to claim 1, which compound is (S)-2-{4'-[4''(2-ethoxy)propoxy]-benzoyloxyphenyl}-5-n-octyloxypyrimidine. A compound according to claim 1, which compound is (S)-2-{4'-[4''(2-methoxy)propoxy]-benzoyloxyphenyl}-5-n-octylpyrimidine. A compound according to claim 2, which compound is (S)-2-{4'-[4''(2-methoxy)propionyloxy]benzoyloxy}phenyl-5-n-octylpyrimidine. A compound according to claim 2, which compound is (S)-2-{4'-[4''(2-butoxy)propionyloxy]benzoyloxy}phenyl-5-n-octylpyrimidine. A compound according to claim 2, which compound is (S)-2-{4'-[4''(2-butoxy)propionyloxy]benzoyloxy}phenyl-5-n-octyloxypyrimidine. A ferroelectric liquid crystal composition including at least one pyrimidinylphenyl ester compound as claimed in any preceding claim.

Inventors: HARADA TAKAMASA C O SEIKO INST, NONOGUCHI HIROSHI C O TEIKOKU, OHBA KAZUMASA C O TEIKOKU CHEM, TAGUCHI MASAAKI C O SEIKO INST, HARADA, TAKAMASA C/O SEIKO INSTRUMENTS INC., NONOGUCHI, HIROSHI C/O TEIKOKU CHEM. IND. CO. LTD., OHBA, KAZUMASA C/O TEIKOKU CHEM. IND. CO. LTD., TAGUCHI, MASAAKI C/O SEIKO INSTRUMENTS INC.
Applicants: SEIKO INSTR INC, TEIKOKU CHEM IND CO LTD, SEIKO INSTRUMENTS INC., TEIKOKU CHEMICAL INDUSTRY CO., LTD.
Application year: 1987
Main classification: C07D239
IPC codes: C09K19, C07D239